Denifanstat

SKU: orb1308311

Description

Denifanstat (FASN-IN-2, TVB-2640) is a selective, orally active fatty acid synthase (FASN) inhibitor with reported IC50 and EC50 values of 0.052 µM and 0.072 µM, respectively. By inhibiting FASN, denifanstat reduces de novo lipogenesis, a key pathway involved in fatty acid production and metabolic regulation.

Research Area

Metabolism Research

Key Properties

• CAS Number: 1399177-37-7
• MW: 439.55
• Purity: 99.44% (May vary between batches)
• Formula: C₂₇H₂₉N₅O
• SMILES: Cc1n[nH]c(n1)-c1cc(C(=O)N2CCC(CC2)c2ccc(cc2)C#N)c(C)cc1C1CCC1
• Target: Fatty Acid Synthase
• Solubility: DMSO: 262.5 mg/mL (597.2 mM), sonication is recommended.

Bioactivity

• Target IC50:
  FASN:0.072 μM (EC50)|FASN:0.052 μM
• In Vivo:
  METHODS: To assay antitumor activity in vivo, Denifanstat (100 mg/kg, 30% PEG400) was administered by gavage to SCID mice bearing PC-3M/HOXB13KD xenografts once daily for six weeks. RESULTS: Five weeks after inoculation, HOXB13-KD mice showed significant metastasis in IVIS, which was completely alleviated by Denifanstat treatment.Denifanstat treatment significantly prolonged metastasis-free survival in both control and HOXB13-KD mice.
  Read more...
• In Vitro:
  METHODS: MDA-MD-231 and MDA-MB-231-BR cells were treated with Denifanstat (1-10.3 µM) for 6-30 h. Cell migration was detected by wound healing assay. RESULTS: Cell migration was inhibited in MDA-MB-231-BR cells but not in parental MDA-MD-231 cells in a dose-dependent manner.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ASC40, ASC-40, ASC 40, COVID-19, Denifanstat, Inhibitor, FASN-IN-2, FASN, Fatty Acid Synthase (FASN), Fatty Acid Synthase, FattyAcidSynthase, inhibit, SARS-CoV2, spike, protein, TVB 2640, TVB2640, TVB-2640

Compound Identifiers

PubChem CID

66548316